美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,456.92

-35.2661-2.36%

涨家数：4

跌家数：3

平家数：- -

市盈率：- -

高：1,485.06

开：1,483.83

低：1,455.39

收：1,492.17

数据加载中...

总览新闻资讯

【欧股“十一罗汉”｜诺和诺德收涨超1.4%，阿斯麦涨约0.5%】周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。

辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官

Altimmune, Inc.盘中异动快速跳水5.02%

Viking Therapeutics, Inc.盘中异动早盘急速下跌5.20%报32.30美元

生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道

安进承诺今年将在印度新技术中心投资约2亿美元

安进公司首席执行官表示，计划投资 2 亿美元建设印度生产基地

上市近一年未有销售，惨遭辉瑞放弃

佰傲谷BioValley

华泰证券：国产GLP-1产品有望抢占全球市场份额

辉瑞：退出基因疗法赛道

速递｜复合药物（Compound）时代终结，认准诺和诺德和礼来正品原研药

GLP1减重宝典

礼来的新筹码

诺和诺德：副总裁离职

辉瑞中国区副总裁、首席医学事务官曹峻洋：中国在全球新药临床研究和学术推动中的贡献越来越大

每日经济新闻

美FDA宣布司美格鲁肽不再短缺，为何诺和诺德(NVO.US)股价大涨？

智通财经网

中国研究人员发现蝙蝠病毒进入人类细胞的途径与 COVID 相同

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4599/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1456.9071,"timestamp":1741289331226,"preClose":1492.1732,"halted":0,"volume":34938655,"delay":0,"changeRate":-0.023634,"change":-35.266113,"pbRate":11.780703,"amount":3284800779.080107,"amplitude":0.019884,"prevYearClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"turnoverRate":0.00331,"marketCap":1567368570880,"floatMarketCap":1455136551296,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1485.0612,"amplitude":0.019884,"preClose":1492.1732,"low":1455.3911,"pbRate":"11.780703","latestPrice":1456.9242,"volume":34935574,"delay":0,"open":1483.8325,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"sixtyDayClose":1438.0239,"secType":"PLATE","market":"US","turnoverRate":0.003309,"peRate":41.703544,"marketCap":1567354742784,"floatMarketCap":1455106634112,"timestamp":1741289329566,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":4,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514666774","title":"【欧股“十一罗汉”｜诺和诺德收涨超1.4%，阿斯麦涨约0.5%】周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514666774","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514666774?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 01:50","pubTimestamp":1740419418,"startTime":"0","endTime":"0","summary":"周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25015048358625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["STM","IE0004445239.USD","BK4182","ASML","LU0097036916.USD","LU2506951792.HKD","159813","LU0211331839.USD","NVS","BK4585","IE00B2B36J28.USD","BE","LU2236285917.USD","IE00BJJMRZ35.SGD","BK4541","LRLCY","LU2294711713.HKD","BK4141","BK4007","IE00BJT1NW94.SGD","NSRGY","LU1642822529.SGD","BK4605","LU2063271972.USD","BK4568","BK4147","GSK","BK4554","LU1093756325.SGD","LU1815336760.USD","LU2417539215.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0444973449.USD","IE00BMPRXN33.USD","LU1829250122.USD","IE00BD6J9T35.USD","BK4578","AZN","BK4212","IE00BFTCPJ56.SGD","01477","GSK.UK","LU1093756168.USD","BK4599","NVO","03165","159582","LU0823434583.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2514755647","title":"辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2514755647","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514755647?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 00:13","pubTimestamp":1740413621,"startTime":"0","endTime":"0","summary":"辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官路透社2月24日 - 辉瑞PFE.N周一表示，美国食品及药物管理局药物中心前负责人帕特里齐亚-卡瓦佐尼将加入该公司，担任首席医疗官。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3T3PF182:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","LU0122379950.USD","LU1894683264.USD","BK4592","IE00BLSP4239.USD","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","SG9999013999.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU1066051498.USD","LU0321505868.SGD","BK4585","LU1883839398.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","SG9999002232.USD","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225771236.USD","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":0},{"id":"2513720245","title":"Altimmune, Inc.盘中异动 快速跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513720245?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 23:02","pubTimestamp":1740409376,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时02分，Altimmune, Inc.股票出现异动，股价大幅下挫5.02%。截至发稿，该股报6.11美元/股，成交量30.6286万股，换手率0.43%，振幅5.19%。Altimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为156.69%、69.94%、25.47%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Altimmune, Inc.公司简介：Altimmune Inc 从事开发治疗肥胖症和肝病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230256a2521c30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230256a2521c30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALT","BK4139","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2513727908","title":"Viking Therapeutics, Inc.盘中异动 早盘急速下跌5.20%报32.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513727908?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 22:32","pubTimestamp":1740407523,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时32分，Viking Therapeutics, Inc.股票出现异动，股价快速下挫5.20%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223203abdb0df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4599","BK4588","LENZ","VKTX"],"gpt_icon":0},{"id":"2513272743","title":"生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272743","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513272743?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 18:22","pubTimestamp":1740392540,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物科技巨头安进公司首席执行官罗伯特·布拉德韦周一在印度海得拉巴大型基地落成典礼上表示，公司今年将向其位于印度南部的这一新建成的技术中心投资大约2亿美元，并计划未来追加更大规模投资。安进将在2025年向该中心投入首期2亿美元资金，并计划未来数年追加重大投资。本周海得拉巴还将举办BioAsia生物科技大会，安进、礼来、诺华等全球跨国药企高管及多家印度制药巨头高管将发表演讲。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253481.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"生物科技巨头安进2亿美元投资印度，押注“AI+制药”赛道","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0868494617.USD","BK4599","BK4139","BK4566","AMGN","LU1983299246.USD","BK4534","LU0889565916.HKD","BK4533","BK4588","LU1057294990.SGD","LU1061106388.HKD","LU2242652126.USD","LU1023059063.AUD","BK4585","BK1191","LU0109394709.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1571399168.USD","BK1574","SG9999001440.SGD","LU0320765992.SGD","LU0122379950.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0289739699.SGD","BK4581","IE0002141913.USD"],"gpt_icon":0},{"id":"2513715981","title":"安进承诺今年将在印度新技术中心投资约2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513715981","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513715981?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 14:57","pubTimestamp":1740380227,"startTime":"0","endTime":"0","summary":"格隆汇2月24日｜据路透，美国制药商安进公司首席执行官Robert Bradway周一表示，该公司今年将在其位于印度南部的新技术中心投资约2亿美元，并计划在未来几年进一步投资。安进公司去年宣布计划在印度开设一个“技术与创新”中心，重点是增加人工智能和数据科学的使用以支持新药的开发。据悉，位于印度特伦甘纳邦首府海得拉巴的工厂到今年年底预计将拥有约2000名员工，目前已有约300名员工在那里工作。本周，该市还将主办BioAsia会议，安进、礼来和诺华等全球制药公司的高管以及几家印度制药巨头将在会上发言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224145719962e1a65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224145719962e1a65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","BK4534","BK4139","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4581","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU2242652126.USD","AMGN","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4599","BK4533","LU1983299246.USD","BK4588","BK4566","LU1061106388.HKD","IE00B2B36J28.USD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","IE0002141913.USD","SG9999001440.SGD","IE0009355771.USD","LU0122379950.USD","LU0868494617.USD","LU1571399168.USD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2513718164","title":"安进公司首席执行官表示，计划投资 2 亿美元建设印度生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2513718164","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513718164?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 14:24","pubTimestamp":1740378261,"startTime":"0","endTime":"0","summary":"安进公司首席执行官表示，计划投资 2 亿美元建设印度生产基地路透社海德拉巴2月24日 - 美国制药商安进公司（Amgen AMGN.O）首席执行官罗伯特-布拉德韦（Robert A. Bradway）在印度南部新技术中心落成典礼上表示，该公司今年将投资约2亿美元，并计划进一步投资。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3S3PF0C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU2242652126.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","AMGN","BK4534","IE00BJT1NW94.SGD","LU0122379950.USD","IE0009355771.USD","BK4588","LU1983299246.USD","LU2242646821.SGD","LU0289739699.SGD","LU0868494617.USD","LU1057294990.SGD","BK4139","LU1061106388.HKD","LU0889565916.HKD","BK4566","LU0109394709.USD","BK4585","BK4581","LU0058720904.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4533","BK4599","LU2112291526.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2513718706","title":"上市近一年未有销售，惨遭辉瑞放弃","url":"https://stock-news.laohu8.com/highlight/detail?id=2513718706","media":"佰傲谷BioValley","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513718706?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 12:02","pubTimestamp":1740369720,"startTime":"0","endTime":"0","summary":"近日，根据媒体报道，辉瑞的一位发言人证实，辉瑞正在停止其血友病B基因治疗药物Beqvez的所有的开发和商业化活动。同时，辉瑞发言人证实，自获批以来，未有商业患者接受过Beqvez治疗。辉瑞退出病毒载体基因治疗辉瑞放弃Beqvez的决定，基本上标志着辉瑞退出了病毒载体递送的基因代替治疗领域。2023年7月，辉瑞将早期研发阶段的基因治疗卖给了阿斯利康旗下的罕见病部门Alexion。辉瑞随即放弃了该疗法的一切开发。2025年2月，辉瑞终止商业化的Beqvez。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-24/doc-inemqazp0162941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0234572021.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU0170899867.USD","LU0321505868.SGD","BK4534","LU1883839398.USD","BK4533","LU0225284248.USD","LU1894683348.USD","LU1057294990.SGD","BK4588","LU0306806265.USD","IE00BBT3K403.USD","LU1023059063.AUD","SG9999013999.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0321505439.SGD","LU1894683264.USD","SGXZ57979304.SGD","BK4585","LU0456855351.SGD","SG9999001176.SGD","IE00BLSP4239.USD","SG9999002232.USD","SG9999011175.SGD","BK4592","LU0225771236.USD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","BK4599","LU0868494617.USD","LU0985481810.HKD","BK4007","BK4581","PFE","LU0306807586.USD","SG9999001176.USD","LU1066051498.USD","LU0058720904.USD","SG9999002224.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","SG9999003800.SGD","BK4550"],"gpt_icon":1},{"id":"2513798267","title":"华泰证券：国产GLP-1产品有望抢占全球市场份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2513798267","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513798267?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 10:02","pubTimestamp":1740362546,"startTime":"0","endTime":"0","summary":"2月24日，华泰证券发布医药健康行业深度研究报告称，GLP-1已展现较大的市场潜力，而目前海外MNC仅诺和诺德和礼来两巨头销售领先，但尚未形成完整产品矩阵，其他MNC产品仍处于临床阶段，竞争格局尚未定型，产品空缺较大。而2023年至今国产GLP-1出海交易频现，华泰证券认为国产GLP-1产品竞争力不输海外，其中GLP-1口服小分子、GLP-1/GIP、GLP-1/GIP/GCGR、GLP-1/GCGR/FGF21、ActRII等靶点不乏临床进展领先的优质资产，未来有望借助BD进军全球市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100328962dd889&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100328962dd889&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMGN","BK4581","LU0868494617.USD","LU1057294990.SGD","LU2242652126.USD","IE0009355771.USD","IE00B2B36J28.USD","BK4585","IE00BJJMRZ35.SGD","BK4534","BK4566","LU0889565916.HKD","IE00BJT1NW94.SGD","BK4588","LU1571399168.USD","BK4139","LLY","BK4144","LU0109394709.USD","LU2242646821.SGD","LU1983299246.USD","GLP","IE0002141913.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0289739699.SGD","BK4590","LU1061106388.HKD","BK4599","NVO","BK4533","LU0320765992.SGD","LU0058720904.USD","SG9999001440.SGD","LU0122379950.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2513791379","title":"辉瑞：退出基因疗法赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2513791379","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513791379?lang=zh_cn&edition=fundamental","pubTime":"2025-02-23 19:00","pubTimestamp":1740308434,"startTime":"0","endTime":"0","summary":"此前，辉瑞还终止了与Sangamo合作的A型血友病基因疗法，并撤回镰状细胞贫血疗法Oxbryta。关于此疗法的终止，辉瑞表示，主要原因是“患者和医生对血友病基因疗法兴趣有限”。其实，辉瑞在基因治疗领域早有动作。而且，辉瑞在2023年7月已将早期研发阶段的基因疗法以高达10亿美元的价格卖给了阿斯利康旗下的罕见病部门Alexion。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224104740a251503f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224104740a251503f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2513737818","title":"速递｜复合药物（Compound）时代终结，认准诺和诺德和礼来正品原研药","url":"https://stock-news.laohu8.com/highlight/detail?id=2513737818","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513737818?lang=zh_cn&edition=fundamental","pubTime":"2025-02-23 11:56","pubTimestamp":1740282976,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队2月21日，美国监管机构表示，诺和诺德的减肥和糖尿病药物不再短缺，这一决定预计将限制大众获得廉价复合药的机会。这项裁决表明诺和诺德对 Ozempic 和 Wegovy的供应目前将保持稳定充满信心。此前，诺和诺德还要求FDA将司美格鲁肽列入《可证明的合成困难清单》。复合制造商表示，他们遵守州和联邦法规，从 FDA 注册的公司采购原材料。当 FDA 在 10 月宣布礼来药物短缺结束时，复合制造商提起诉讼，称这些药物仍然供不应求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223202800a250a5bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223202800a250a5bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2360106947.USD","LU1712237335.SGD","LU1720051017.SGD","LU2023250504.SGD","LU1804176565.USD","LU0385154629.USD","LU1127390331.HKD","LU0640476718.USD","LU2324357040.USD","LU0203202063.USD","LU0882574139.USD","LU1868837300.USD","LU0943347566.SGD","LU0417517546.SGD","LU0006306889.USD","SGXZ99366536.SGD","LU2106854487.HKD","IE00BFTCPJ56.SGD","LLY","LU0289739699.SGD","LU0823416689.USD","LU2237443622.USD","LU2211815571.USD","LU2491050154.USD","SG9999013999.USD","BK4588","LU1720051108.HKD","BK4533","IE00BJJMRZ35.SGD","LU2264538146.SGD","BK4599","LU2237443549.SGD","LU2361044865.SGD","SG9999014906.USD","GB00BDT5M118.USD","LU2237443895.HKD","LU1989771016.USD","SGXZ51526630.SGD","LU1917777945.USD","LU1988902786.USD","LU2602419157.SGD","LU0689472784.USD","LU1983299246.USD","SG9999018857.SGD","LU0672654240.SGD","LU1069344957.HKD","LU1280957306.USD","NVO","LU1366192091.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2513923200","title":"礼来的新筹码","url":"https://stock-news.laohu8.com/highlight/detail?id=2513923200","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513923200?lang=zh_cn&edition=fundamental","pubTime":"2025-02-23 07:31","pubTimestamp":1740267061,"startTime":"0","endTime":"0","summary":"在围绕GLP-1的心血管代谢和肥胖症赛道之外，礼来正在布局新筹码：基因药物和核药。虽然，不同的临床试验结果不能直接用来比较，但也可以从侧面看出，礼来LEPODISIRAN在降脂疗效的持久性方面或更胜一筹。以上三款药物均是礼来通过对外收购合作所获得的管线资产。同时，礼来获得未来以10亿美元收购Radionetics的排他权。礼来在核药赛道的布局与研发，意味着在可预测的未来，将与诺华等头部制药企业共同开启肿瘤精准诊疗的新时代。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223073347a2501c04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223073347a2501c04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2237438978.USD","LU2361044865.SGD","LU2491050071.SGD","LU2063271972.USD","SG9999014914.USD","LU1989771016.USD","LU0058720904.USD","LU1988902786.USD","LU1061106388.HKD","GB00BDT5M118.USD","LU2237443895.HKD","LU2106854487.HKD","LU1280957306.USD","LU0823416689.USD","SG9999013999.USD","LU1093756325.SGD","LLY","LU0096364046.USD","LU1917777945.USD","IE00B1BXHZ80.USD","SG9999015978.USD","SG9999015945.SGD","LU0061475181.USD","LU0256863902.USD","LU0820561909.HKD","LU2602419157.SGD","SG9999014906.USD","LU0094547139.USD","LU1720051108.HKD","LU2461242641.AUD","LU1974910355.USD","LU2112291526.USD","LU0456855351.SGD","LU1366192091.USD","BK4599","BK4585","BK4516","IE00BJLML261.HKD","IE00B4R5TH58.HKD","LU0006306889.USD","LU0354030511.USD","LU0672654240.SGD","LU1868836914.USD","LU0471298694.HKD","LU2360106947.USD","SGXZ99366536.SGD","LU0471298777.SGD","LU1983299246.USD","BK4588","LU0820561818.USD"],"gpt_icon":1},{"id":"2513270787","title":"诺和诺德：副总裁离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2513270787","media":"药事纵横","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513270787?lang=zh_cn&edition=fundamental","pubTime":"2025-02-23 00:01","pubTimestamp":1740240104,"startTime":"0","endTime":"0","summary":"近日，诺和诺德宣布，新兴事业部副总裁姜一炜女士将离职，寻求外部机会。姜一炜女士自加入诺和诺德以来，历任多个重要职位，包括胰岛素高级市场总监、诺和诺德香港总经理等。此次人事调整是诺和诺德在全球范围内进行的组织架构优化的一部分，旨在应对市场变化并支持公司战略转型。之前的新兴事业部副总裁是高堃，高堃在诺和诺德工作了24年，从做医药代表起，历任销售经理、区域业务经理、销售总监、区域业务副总裁等职位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000253abd8c82e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000253abd8c82e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756325.SGD","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","BK4599","LU0154236417.USD","NVO","BK4588","IE00BZ1G4Q59.USD","BK4007"],"gpt_icon":1},{"id":"2513627369","title":"辉瑞中国区副总裁、首席医学事务官曹峻洋：中国在全球新药临床研究和学术推动中的贡献越来越大","url":"https://stock-news.laohu8.com/highlight/detail?id=2513627369","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513627369?lang=zh_cn&edition=fundamental","pubTime":"2025-02-22 17:43","pubTimestamp":1740217410,"startTime":"0","endTime":"0","summary":"2月13日—15日，美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCOGU）在美国旧金山召开。ASCOGU是单独针对泌尿生殖系统肿瘤的国际大会，每年来自世界各地的顶级医学专家都希望在这场学术盛会上分享自己的最新成果。今年大会上，辉瑞最受关注的研究之一是TALAPRO-2Ⅲ期临床试验关键结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502223326758222.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502223326758222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2513228246","title":"美FDA宣布司美格鲁肽不再短缺，为何诺和诺德(NVO.US)股价大涨？","url":"https://stock-news.laohu8.com/highlight/detail?id=2513228246","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513228246?lang=zh_cn&edition=fundamental","pubTime":"2025-02-22 10:54","pubTimestamp":1740192840,"startTime":"0","endTime":"0","summary":"当地时间周五，美国食品和药物管理局官网显示，诺和诺德公司报告称司美格鲁肽注射液的短缺和停产情况已经解决。FDA称，诺和诺德现在可以在美国全国范围内满足患者的药物需求。之前有银行家估计，如果司美格鲁肽持续短缺，仿制地减肥药每年能为制造商带来高达10亿美元的收入。去年12月，FDA宣布司美格鲁肽的竞争对手、礼来替尔泊肽的短缺问题已经解决。之后，外包设施协会将FDA告上法庭，他们认为FDA忽视了药物仍然短缺的证据。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2025-02-22/doc-inemikpk2851260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","BK4599","LU0154236417.USD","BK4007","BK4585","BK4588","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2513245187","title":"中国研究人员发现蝙蝠病毒进入人类细胞的途径与 COVID 相同","url":"https://stock-news.laohu8.com/highlight/detail?id=2513245187","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513245187?lang=zh_cn&edition=fundamental","pubTime":"2025-02-22 06:51","pubTimestamp":1740178309,"startTime":"0","endTime":"0","summary":"中国研究人员发现蝙蝠病毒进入人类细胞的途径与 COVID 相同Julie Steenhuysen/Nancy Lapid路透社2月21日 - 中国研究人员报告说，一种新发现的蝙蝠冠状病毒与导致COVID-19的SARS-CoV-2病毒一样，使用相同的细胞表面蛋白进入人体细胞，这使它有一天可能传播给人类。在进一步的实验中，研究人员发现了针对蝙蝠病毒的单克隆抗体和抗病毒药物。彭博社周五早些时候报导了这项研究，并称这篇发现蝙蝠病毒的论文推动了COVID疫苗生产商的股价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3T3PC1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","MRNA","LU0122379950.USD","LU1894683264.USD","BK4592","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","NVAX","LU1057294990.SGD","SG9999002224.SGD","BK4139","BK4547","SG9999002232.USD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4532","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU0321505868.SGD","BK4585","LU1066051498.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","LU1883839398.USD","BK4548","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","BK4551","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":1}],"pageSize":16,"totalPage":7,"pageCount":6,"totalSize":111}]}}